Vaporizers and Health: What Science Says

In brief: Vaporizers heat cannabis below the combustion point, avoiding most of the harmful byproducts created by smoking. Studies show lower carbon monoxide levels in blood, fewer respiratory complaints, and different metabolite profiles in the body.

Heating Instead of Burning: The Basic Principle

A vaporizer heats cannabis to 160–230 °C. At these temperatures, cannabinoids and terpenes are released from the plant material without combustion. Burning only starts above 230 °C.

When a joint or cigarette burns, over 100 different toxins are produced, including:

These include tar, which accumulates in the lungs and impairs gas exchange, carbon monoxide (CO), which displaces oxygen in the blood, benzene, a known carcinogen produced above 300 °C, and particulate matter — fine particles that penetrate deep into lung tissue.

Vaporizing largely eliminates these substances. The vapor consists mainly of cannabinoids, terpenes, and water vapor.

Scientific Studies: Current Evidence

Less Carbon Monoxide in Blood (Abrams et al., 2007)

This study is considered a landmark. 18 healthy participants consumed cannabis through a Volcano vaporizer or smoked the same amount as a joint. The vaporizer group had significantly less carbon monoxide in their blood — while absorbing comparable amounts of THC. Less exposure to toxins, same effectiveness.

Fewer Respiratory Symptoms (Earleywine & Barnwell, 2007)

6,883 cannabis users were surveyed. Those who exclusively vaporized reported less coughing, phlegm, and chest tightness compared to smokers. Even users who alternated between methods had fewer symptoms than exclusive smokers.

Cannabis and Respiratory Conditions (Jarjou’i & Izbicki, 2020)

Researchers at the Hadassah-Hebrew University School of Medicine in Jerusalem reviewed the existing literature on cannabis use in asthmatic patients. Their finding: cannabis has a bronchodilator effect — it widens the airways — and shows anti-inflammatory properties.

At the same time, they made clear that harmful lung effects come primarily from smoking. Smoke irritates the airways and can promote chronic bronchitis. The researchers called for more studies on vaporizers as a way to avoid these harmful side effects.

Different Metabolites from Vaporizing (Huestis et al., 2020)

The National Institute on Drug Abuse compared urinary metabolites after three consumption methods: smoking, vaporizing, and oral intake. 20 participants (11 frequent, 9 occasional users) each received 50.1 mg THC under controlled conditions.

Peak THC-COOH-glucuronide concentrations in urine varied by method:

Method	Frequent Users	Occasional Users
Smoking	68 µg/L	378 µg/L
Vaporizing	27 µg/L	248 µg/L
Oral	360 µg/L	485 µg/L

Smoking produced higher THC-COOH levels than vaporizing — at the same THC dose. This demonstrates that the method of consumption affects how the body metabolizes cannabinoids. Notably, CBD, CBN, CBG, and THCV were not detectable in urine.

Clinical Efficacy Data: NNT, Pharmacokinetics, and Dose-Finding

The following three studies provide hard numbers on three central questions: How effective is vaporized cannabis for pain? How does THC absorption compare to smoking? And can the dose be precisely controlled with a vaporizer?

Wilsey et al.: NNT for Neuropathic Pain

Barth Wilsey and colleagues at UC Davis studied 39 patients with central and peripheral neuropathic pain in a double-blind, placebo-controlled, crossover trial. All participants inhaled cannabis via a Volcano vaporizer under three conditions: placebo, low dose (1.29% THC), and medium dose (3.53% THC).

The key result is the NNT (Number Needed to Treat) — how many patients must be treated for one to achieve at least 30% pain reduction:

Comparison	NNT (30% Pain Reduction)
Placebo vs. Low Dose (1.29% THC)	3.2
Placebo vs. Medium Dose (3.53% THC)	2.9
Medium Dose vs. Low Dose	25

These numbers stand out. For context: gabapentin has an NNT of about 5.9, pregabalin sits around 7.7. Vaporized cannabis performed considerably better than standard neuropathic pain medications in this trial.

The third row is the real surprise. An NNT of 25 between medium and low dose means there was virtually no difference between the two (p > 0.7). In practical terms: the low dose worked nearly as well as the medium dose. Psychoactive effects at 1.29% THC were minimal, and cognitive changes reversed fully within one to two hours.

This has direct clinical implications. Low-dose cannabis reduces the risk of recreational diversion because the intoxicating effect stays low — while pain relief remains comparable.

Abrams et al. 2007: Pharmacokinetic Comparison of Vaporizer vs. Smoking

Donald Abrams and his team at San Francisco General Hospital conducted the first systematic pharmacokinetic comparison. 18 healthy subjects spent six days in an inpatient setting, consuming cannabis at three THC strengths (1.7%, 3.4%, 6.8%) — alternating between a Volcano vaporizer and smoked joints. Inhalation followed the standardized Foltin Puff Procedure: 5 seconds inhale, 10 seconds breath hold, exhale, 45 seconds pause, repeat.

Parameter	Vaporizer	Smoked	p-value
AUC₀₋₆ (1.7% THC)	46.0 ng·h/mL	37.3 ng·h/mL	0.23
AUC₀₋₆ (3.4% THC)	69.8 ng·h/mL	75.6 ng·h/mL	0.69
AUC₀₋₆ (6.8% THC)	81.3 ng·h/mL	75.1 ng·h/mL	0.65
Cmax (1.7% THC)	73.4 ng/mL	60.3 ng/mL	0.28
Cmax (6.8% THC)	142.3 ng/mL	135.7 ng/mL	0.81
CO Exposure (AUC)	minimal (−1.9 to −0.5)	significant (7.0–15.5)	<0.001

At the lowest THC concentration (1.7%), the vaporizer delivered nearly double the total THC exposure (AUC ratio 1.99; 90% CI 1.04–3.27). At higher concentrations, values converged — suggesting subjects self-titrated their intake.

The critical difference sits in the last row: carbon monoxide exposure was massively elevated with smoking, essentially zero with vaporizing. 14 of 18 subjects preferred the vaporizer, 2 preferred smoking, 2 had no preference. Zero adverse events were reported.

Zuurman et al. 2008: Dose-Response via Vaporizer

Linda Zuurman and colleagues at the Centre for Human Drug Research in Leiden ran a dose-escalation study using pure THC (dronabinol) delivered through a Volcano vaporizer. 12 healthy subjects inhaled ascending doses of 2, 4, 6, and 8 mg THC at 90-minute intervals.

The study showed dose-dependent changes in heart rate and body sway. What mattered most was the low inter-individual variability in plasma THC levels — a clear advantage of the Volcano over smoking, where THC uptake varies widely between users.

5 of 12 subjects coughed during inhalation (but not during placebo sessions). The authors considered this a minor issue. It was the first study to demonstrate reproducible dose-escalation through a vaporizer — a prerequisite for clinical use.

What These Three Studies Show Together

Abrams establishes that the vaporizer delivers THC as effectively as smoking — without the carbon monoxide burden. Zuurman proves that doses can be scaled precisely via Volcano, with low variability between patients. And Wilsey shows that even low THC doses achieve clinically meaningful pain relief with an NNT of 3.2 — outperforming gabapentin and pregabalin. For patients, the Volcano enables reproducible dosing with a low side-effect profile.

The Cannabis Plant: Strains, Compounds, and Terpenes

The cannabis plant contains far more than just THC and CBD. Over 80 cannabinoids, 120 terpenes, and numerous flavonoids form a complex phytochemical profile that varies considerably between strains. Understanding these compounds is essential for medical use.

Sativa and Indica

Cannabis Sativa grows tall and slender with narrow leaves. Its effects are described as cerebral and energizing — Sativa strains tend toward higher THC content. Cannabis Indica is more compact with broad leaves and is associated with physical relaxation and sedation. Modern medical strains are hybrids bred for specific cannabinoid profiles.

Over 80 Cannabinoids

Beyond THC and CBD, the plant contains dozens of additional cannabinoids, each with its own therapeutic profile:

Cannabinoid	Psychoactive	Therapeutic Effect
THC (Δ9-tetrahydrocannabinol)	Yes	Pain relief, anti-emetic, appetite stimulation
CBD (cannabidiol)	No	Antispasmodic, anxiolytic, anti-inflammatory
CBN (cannabinol)	Mildly	Sedating; forms through THC degradation during storage
CBG (cannabigerol)	No	Antibacterial, neuroprotective, precursor of all cannabinoids
CBC (cannabichromene)	No	Anti-inflammatory, antidepressant, analgesic
THCV (tetrahydrocannabivarin)	Mildly	Appetite suppression, shorter duration than THC

120 Terpenes and Their Effects

Terpenes are aromatic compounds responsible for the cannabis plant’s scent. They possess their own therapeutic properties and influence how cannabinoids interact with the body:

Terpene	Aroma	Effect	Also Found In
Myrcene	Earthy, musky	Sedating, analgesic	Hops, mango, thyme
Limonene	Citrus	Mood elevation, anxiolytic	Citrus fruits, juniper
α-Pinene	Pine, fresh	Alertness, anti-inflammatory	Pine needles, rosemary
Linalool	Floral, lavender	Calming, anxiolytic, analgesic	Lavender, coriander
β-Caryophyllene	Peppery, spicy	Anti-inflammatory, binds directly to CB2 receptor	Black pepper, cloves

The Entourage Effect

Cannabinoids and terpenes do not act in isolation. The combination of all plant constituents produces a stronger therapeutic effect than the sum of individual compounds. Myrcene enhances the analgesic effect of THC; linalool complements the anxiolytic properties of CBD. β-Caryophyllene is the only known terpene that binds directly to the CB2 receptor of the endocannabinoid system — providing anti-inflammatory action without psychoactive effects.

The entourage effect explains why whole-plant cannabis is often more effective in clinical studies than isolated dronabinol (synthetic THC).

Medical Cannabis Strains: The Bedrocan Program

The Dutch manufacturer Bedrocan BV — the world’s first pharmaceutical cannabis producer — supplies standardized strains with precisely defined cannabinoid content:

Strain	THC	CBD	Type	Therapeutic Focus
Bedrocan	22 %	< 1 %	Sativa	THC-dominant, broadly applicable
Bedrobinol	13.5 %	< 1 %	Sativa	Moderate THC potency
Bediol	6.3 %	8 %	Sativa	Balanced, less psychoactive
Bedica	14 %	< 1 %	Indica	Body-focused, sedating
Bedrolite	< 1 %	9 %	Sativa	CBD-dominant, non-psychoactive

The physician selects the strain based on the condition, desired effect, and individual tolerance. The patient controls intensity through the vaporization temperature: lower temperatures (180 °C) primarily release terpenes and CBD, higher temperatures (210 °C) maximize THC extraction.

The Endocannabinoid System: Why Cannabis Works

In the early 1990s, researchers discovered that the human body produces its own cannabis-like substances — the endocannabinoids. This internal system regulates sleep, appetite, pain perception, mood, and immune function.

Two receptor types play a central role:

CB1 receptors are located primarily in the brain — in the cerebellum, hippocampus, and cerebral cortex. They influence sensory perception, memory, and motor skills. THC docks onto CB1 as a partial agonist, intensifying the senses of touch, smell, and taste. CB2 receptors, by contrast, are found mainly in the immune system and on white blood cells, where they attenuate inflammation and allergic reactions.

A medically important detail: the brain stem, which controls vital functions such as breathing and circulation, has no CB1 receptors. A cannabis overdose is therefore not life-threatening under normal circumstances — vital functions remain unaffected.

THC and CBD: Two Active Compounds Working Together

Of the more than 80 known cannabinoids, two are medically relevant: THC (Δ9-tetrahydrocannabinol) and CBD (cannabidiol). In the plant, THC exists as inactive THCA acid. Only through heating — decarboxylation — does the psychoactive Δ9-THC form above 180 °C.

CBD is not psychoactive but has antispasmodic and muscle-relaxing properties. Studies show that pure THC alone can trigger anxiety and restlessness in some patients. Only in combination with CBD is the effect perceived as pleasant. The THC-to-CBD ratio significantly influences the effect profile of each cannabis strain.

Cannabis also contains around 120 different terpenes — aromatic compounds that create the characteristic scent and additionally influence the effect profile.

Endogenous Cannabinoids: Anandamide and 2-AG

The human body produces its own cannabinoids — no cannabis plant needed. In 1992, Israeli chemist Raphael Mechoulam isolated the first endocannabinoid: anandamide (N-arachidonoylethanolamine). He named it after the Sanskrit word “ananda,” meaning bliss. Three years later, Mechoulam and Japanese researcher Sugiura independently identified 2-AG (2-arachidonoylglycerol) — the most abundant endocannabinoid in the human body.

Both substances function as retrograde neurotransmitters. They are released by the postsynaptic neuron and travel backward to the presynaptic neuron, where they regulate signal strength. This mechanism is unique in neurobiology.

Researchers now know of at least five endocannabinoids:

Endocannabinoid	Receptor Affinity	Primary Function	Discovery
Anandamide (AEA)	CB1 > CB2	Pain modulation, mood, appetite	1992 (Mechoulam)
2-AG	CB1 = CB2	Immune regulation, neuroprotection, inflammation	1995 (Mechoulam/Sugiura)
Virodhamine	CB2 > CB1	Partial antagonist, thermoregulation	2002
Noladin ether	CB1	Sedation, hypothermia	2001
NADA	CB1, TRPV1	Pain signaling (vanilloid receptor crosstalk)	2000

Retrograde Signaling: A Unique Mechanism

Classical neurotransmitters like serotonin or dopamine travel in one direction: from the presynaptic to the postsynaptic neuron. Endocannabinoids do the opposite. They are synthesized on demand in the postsynaptic neuron and travel backward to the presynaptic neuron.

Here is how it works: when a postsynaptic neuron is overstimulated, it releases endocannabinoids. These bind to CB1 receptors on the presynaptic neuron and reduce neurotransmitter release. Scientists call this “retrograde signaling” — essentially a natural brake mechanism.

This principle explains several therapeutic effects of cannabis:

In epileptic seizures, excessive neural firing is dampened. In pain conditions, the transmission of pain signals is reduced. In spasticity, overactive motor neurons are downregulated.

Plant cannabinoids like THC mimic this endogenous process — they bind to the same receptors normally used by anandamide and 2-AG.

Clinical Endocannabinoid Deficiency

In 2004, neurologist Ethan Russo proposed the hypothesis of “Clinical Endocannabinoid Deficiency” (CED). His theory: certain chronic conditions — particularly migraine, fibromyalgia, and irritable bowel syndrome (IBS) — may result from insufficient endocannabinoid tone.

These three conditions share striking commonalities: they involve central sensitization, are comorbid with each other at rates exceeding chance, respond poorly to conventional treatments — but improve with cannabinoid therapy.

If the CED hypothesis is confirmed, it would explain why medical cannabis helps patients for whom other treatments have failed. In this model, cannabis supplements a deficient regulatory system rather than merely masking symptoms.

Russo updated his hypothesis in 2016 with new clinical data. Research remains active — definitive proof is still pending, but the evidence is building.

Medical Cannabis: Vaporizers in Practice

Fibromyalgia Patients and Cannabis (Habib & Levinger, 2020)

Israeli researchers at Laniado Hospital in Netanya followed 109 fibromyalgia patients using medical cannabis. They tracked diagnosis duration, consumption frequency, preferred method, and symptom changes over time.

Key findings:

54% of patients smoked cannabis, 18% used a vaporizer, and 3% used oil only. Average consumption frequency was 4.1 times per day, with a peak of 8 times. 77% reported improvements in sleep and pain, and nearly half were able to discontinue or reduce other medications. Notably, all patients said they would recommend cannabis treatment for relatives with severe fibromyalgia.

The authors noted that vaporizing is gaining ground as a consumption method in medical settings. The proportion is steadily growing — in part because physicians increasingly advise against smoking medical cannabis.

Combustion vs. Vaporization: The Toxicological Difference

When cannabis is smoked, the plant material burns at over 600 °C. This produces the same toxic combustion byproducts as tobacco smoke — regardless of whether tobacco is mixed in or not. Vaporization at 180–210 °C avoids this combustion entirely.

Harmful Substances from Combustion

The following table shows the main combustion byproducts and their health effects:

Pollutant	Health Effect	Present in Vapor?
Tar (condensate)	Carcinogenic, coats respiratory mucosa	Not detectable
Carbon monoxide (CO)	Binds to hemoglobin, reduces oxygen transport	Not detectable
Benzene	Carcinogenic (leukemia risk)	Not detectable
Toluene	Neurotoxic, headaches, dizziness	Not detectable
Naphthalene	Carcinogenic, respiratory irritation	Not detectable
Polycyclic aromatic hydrocarbons (PAHs)	Carcinogenic, DNA damage	Not detectable
Hydrogen cyanide (HCN)	Inhibits cellular respiration	Not detectable
Acrolein	Irritates airways, damages epithelial tissue	Not detectable

95 % Fewer Harmful Substances

Studies show that cannabis vapor contains approximately 95 % fewer harmful byproducts compared to cannabis smoke. The vapor consists primarily of cannabinoids and terpenes — the therapeutically active substances. Airway irritation from vaporization is not zero, but drastically lower than from smoking.

Why Smoking Is Not Medically Accepted

Medical professional societies worldwide reject smoking cannabis as a method of administration — despite its rapid onset of effect. The carcinogenic and airway-damaging combustion byproducts negate the therapeutic benefit. Vaporization offers the same rapid onset (1–2 minutes) without exposing the lungs to the products of pyrolysis.

A common misconception: cannabis smoke is “more natural” than tobacco smoke. In reality, cannabis smoke contains many of the same carcinogens — combustion chemistry depends not on the plant material, but on temperature. Anything heated above 230 °C potentially produces toxic pyrolysis products.

Lab Data: What Exactly Is in the Vapor?

Two independent studies analyzed Volcano vapor under controlled laboratory conditions. Both were published in peer-reviewed journals and provide hard numbers rather than guesswork.

Gieringer et al. 2004 – Vapor vs. Smoke, Head to Head

Dale Gieringer and colleagues at Chemic Laboratories examined Volcano vapor using GC/MS and HPLC. They used 200 mg of NIDA-grade cannabis (4.15% THC) at the device’s maximum temperature setting (roughly 155–218 °C). The study was funded by MAPS and published in the Journal of Cannabis Therapeutics.

The contrast was stark:

Parameter	Volcano Vapor	Smoke (Combustion)
Identified compounds (gas phase)	5 (THC, CBN, caryophyllene + 2 trace compounds)	111
PAHs (polycyclic aromatic hydrocarbons)	0	8 (incl. benz[a]pyrene, naphthalene)
Cannabinoid share of total mass	94.3%	12%
THC delivery efficiency (lab)	36–61%	78% (no sidestream loss)
Combusted material	No (intact, dehydrated)	Yes (ash)

That 78% combustion figure only applies under lab conditions with zero sidestream loss. In real-world joint smoking, THC delivery drops to 16–19% according to Davis (1984), because most of the material burns away between puffs.

Under the microscope, the post-vaporization residue told its own story. The resin glands (trichomes) had shriveled and the resin had evaporated, but the plant matter itself remained intact — just dehydrated. No ash, no charring.

Hazekamp et al. 2006 – Precision Testing with Pure THC

At Leiden University, Arno Hazekamp tested the Volcano using pure THC (≥ 98% purity) instead of plant material. This removed all botanical variables and allowed an exact mass balance. Published in the Journal of Pharmaceutical Sciences.

Parameter	Value
Mean THC delivery into the balloon	53.9% (± 8.1%)
Dose linearity (R²)	0.99
Condensation loss after 5 minutes	< 2%
Condensation loss after 180 minutes	~100% (no THC detectable)
THC residue on the liquid pad	< 5%
Condensation on the filling chamber	23.6% (± 14.1%)
Exhaled THC	~35%
Final pulmonary uptake	30–40% of the loaded dose

Four different Volcano units showed low interdevice variability. Even at maximum temperature, no degradation products like delta-8-THC or CBN were detected. The optimal balloon volume was 8 liters, with a fill time of about 55 seconds.

One practical takeaway: a filled balloon loses THC to condensation on its inner walls surprisingly fast. After three hours, virtually nothing remained detectable in the vapor.

Why Vaporization Works: The Temperature Threshold

A cigarette coal reaches 800–900 °C during a puff and 700–800 °C between puffs (Baker 1974). Even at the periphery, temperatures still hit about 300 °C. Cannabis contains roughly 500 chemical compounds, and pyrolysis generates over 200 additional breakdown products from those.

White et al. (2001) demonstrated via the Ames Salmonella test that mutagenicity kicks in at around 400 °C. The Volcano tops out at 218 °C — well below that threshold. That gap explains why Gieringer found just 5 compounds in vapor instead of 111.

Particle Size: What Reaches the Lungs?

Researchers at Northeastern University in Boston (Farra et al., 2020) developed a mouse model to study cannabis aerosol from a vaporizer in detail. They vaporized cannabis containing 10% THC and 0.05% CBD and analyzed the resulting particles.

Result: particles had a mean diameter of 243 ± 39 nanometers (geometric standard deviation: 1.56). For comparison: cigarette smoke typically contains particles ranging from 100–1,000 nm, with the majority between 300 and 500 nm.

The animal model was validated as suitable for investigating the long-term effects of vaporized cannabis inhalation in controlled studies — a research tool that was previously unavailable.

MMAD: The Key Metric

MMAD stands for Mass Median Aerodynamic Diameter — the particle size at which 50% of the aerosol mass is contained in larger particles and 50% in smaller ones. This single number determines where in the respiratory tract particles deposit, and therefore whether an active compound actually reaches the lungs.

Particle size (MMAD)	Deposition zone	Clinical relevance
10 µm	Nose/mouth (filtered out)	No lung exposure
5–10 µm	Pharynx, larynx	Upper airway irritation
2–5 µm	Bronchi, bronchioles	Good absorption, some local effects
0.5–2 µm	Alveoli (gas exchange zone)	Optimal absorption into bloodstream
< 0.5 µm	Remain suspended, exhaled	Poor deposition, wasted

The therapeutic sweet spot sits at 0.5–3 µm. Particles in this range reach the alveoli, where the epithelium is just 0.1–0.2 µm thin — thin enough for rapid diffusion into the blood.

Vaporizers vs. Medical Inhalers

How do vaporizers stack up against conventional medical inhalation devices? The numbers paint a striking picture.

Device	MMAD	Respirable fraction	Use case
Volcano Medic 2 (Balloon)	0.2–3.5 µm	~95%	Cannabis medical therapy
Volcano Medic 2 (Tube)	0.2–3.5 µm	~93%	Cannabis medical therapy
Metered-dose inhaler (MDI)	2–5 µm	10–40%	Asthma/COPD
Nebulizer	1–5 µm	15–50%	Various respiratory drugs
Dry powder inhaler (DPI)	1–5 µm	20–50%	Asthma/COPD
Cigarette smoke	0.1–1 µm	80%	No medical use

The Volcano achieves a respirable fraction of roughly 95% — meaning 95% of all generated particles fall within the size range that actually reaches the lungs. Conventional medical inhalers manage 10–50%. The reason: the Volcano’s convection heating produces an exceptionally uniform aerosol with consistent particle sizes. Metered-dose inhalers, by contrast, depend on propellant mechanics and patient coordination.

Farra et al. (2020) measured a geometric mean diameter of 243 nm (0.243 µm) for the Volcano aerosol — squarely in the alveolar deposition zone. These ultra-fine particles explain the high bioavailability of 50–56% and the rapid onset of 1–2 minutes observed in clinical studies.

Bioavailability: How Much Gets Absorbed?

A key advantage of vaporizing over other consumption methods is bioavailability — the proportion of active ingredients that actually reaches the bloodstream.

Measurements using the Volcano Medic 2 at 210 °C show (Hazekamp et al., 2006):

Method	Bioavailability
Vaporizer (Balloon)	approx. 50%
Vaporizer (Tube)	approx. 43%
Oral ingestion	below 15%

In practical terms: from 100 mg of cannabis containing 19 mg THC, the balloon captures about 15 mg in vapor and roughly 10 mg enters the bloodstream. Taken orally, less than 3 mg would be absorbed. Vaporizing delivers more than three times the active compound from the same starting material.

A temperature of 210 °C has proven optimal in studies: at this setting, THCA, CBDA, and most terpenes are released almost completely — without combustion occurring.

Pharmacokinetics: How THC Travels Through the Body

How fast does cannabis take effect — and why do the outcomes vary so much depending on the method of consumption? The answer lies in pharmacokinetics: the path THC takes through the body. The table below summarizes the key parameters for vaporizer inhalation, oral ingestion, and smoking.

Parameter	Inhalation (Vaporizer)	Oral (Capsules/Oil)	Smoking (Joint)
Tmax (peak blood plasma)	3–10 minutes	60–120 minutes	3–10 minutes
Bioavailability	35–56%	6–20%	15–25%
Duration of effect	2–4 hours	4–8 hours	2–4 hours
Onset	1–2 minutes	30–90 minutes	Seconds to minutes
Metabolites	11-OH-THC (low)	11-OH-THC (high)	11-OH-THC (low)
Dosing precision	High (titratable)	Low (delayed feedback)	Low (variable combustion)

Vaporization achieves a bioavailability of 35–56% — roughly double that of smoking (15–25%) and up to nine times higher than oral intake (6–20%). The reason smoking delivers fewer cannabinoids than a vaporizer: combustion destroys 30–50% of the cannabinoids before they can even be inhaled. With a vaporizer, nearly all active compounds are released intact and pass directly from the lungs into the bloodstream.

Metabolism and Half-Life

After absorption, THC is rapidly metabolized in the liver via the enzymes CYP2C9 and CYP3A4. The first metabolite is 11-OH-THC — pharmacologically active and capable of crossing the blood-brain barrier even more efficiently than THC itself. It is then converted into 11-COOH-THC, an inactive metabolite that is excreted via urine.

The critical difference between inhalation and oral consumption lies in first-pass metabolism: orally ingested THC passes through the liver first, where up to 90% is converted to 11-OH-THC before reaching systemic circulation. Since 11-OH-THC is more psychoactive than THC and persists longer in the body, this explains why oral cannabis effects tend to be stronger, less predictable, and longer-lasting than those from inhalation.

THC is extremely lipophilic (fat-soluble) and accumulates in adipose tissue. The plasma half-life is 1–3 days, but the terminal elimination half-life can reach 5–13 days in regular users. This is precisely why THC remains detectable in urine for weeks after last use — it slowly leaches back from fat stores into the bloodstream.

For patients using cannabis regularly, this lipophilic accumulation means that steady-state plasma levels are reached after roughly 4–5 days. This provides a more consistent baseline effect over time and makes individual dose adjustments easier.

Pharmaceutical Quality: What Matters

Medical cannabis is not a uniform product. THC and CBD content varies considerably between strains — from THC-dominant varieties (19% THC, below 1% CBD) to balanced strains (6% THC, 7.5% CBD). For reliable dosing, both physician and patient need to know the exact cannabinoid content.

Strict quality requirements apply:

Standardized cultivation forms the foundation — only cannabis from controlled, reproducible cultivation is suitable for medical use, while wild or home-grown plants cannot provide reliable cannabinoid levels. Each batch undergoes contamination testing for bacteria, mold, fungicides, and pesticides. Manufacturers such as Bedrocan BV in the Netherlands produce under GMP certification (Good Manufacturing Practice) and are supervised by the Dutch Ministry of Health.

In Germany, medical cannabis has been available on prescription since March 2017. Costs may be covered by health insurance under certain conditions.

Medical Indications

Cannabis is used therapeutically for various conditions. The best-documented applications:

Indication	Effect
Chronic pain	Effective for neuropathic pain (MS, arthritis, cancer pain). Limited effect on acute pain.
Spasticity / muscle cramps	Study with 572 patients: 47.6% improvement. Spasticity reduced by more than 20%.
Nausea / vomiting	Similar or stronger effect than conventional antiemetics during chemotherapy.
Loss of appetite	THC stimulates appetite. Used for anorexia and HIV-related weight loss.

Other applications with less data: Tourette syndrome, ADHD, PTSD, epilepsy, and itching. In Germany, medical cannabis has been available by prescription since 2017.

Smoking is explicitly considered a non-accepted administration method in medical literature, as combustion byproducts (polycyclic aromatic hydrocarbons, ammonia, carbon monoxide) undermine therapeutic benefits. Vaporization is the preferred inhalation method.

Indications in Numbers: 572 Patients

A survey of 572 patients prescribed medical cannabis shows the distribution of therapeutic applications:

Indication	Proportion	Typical Cannabinoids
Chronic pain	approx. 47%	THC-dominant or THC/CBD blend
Spasticity (e.g., multiple sclerosis)	approx. 20%	THC/CBD blend
Nausea/vomiting (chemotherapy)	approx. 11%	THC-dominant
Appetite loss (HIV/AIDS, cachexia)	approx. 5%	THC-dominant
Tourette syndrome	approx. 3%	THC-dominant
ADHD (off-label)	approx. 2%	Individual
Other (depression, PTSD, glaucoma, epilepsy)	approx. 12%	Varies by condition

The evidence is strongest for chronic pain and spasticity. For Tourette syndrome and ADHD, fewer controlled studies exist — prescription is made on an individual basis.

Oral Administration: Methods and Limitations

Before medical vaporizers were introduced, oral intake was the primary route of administration. It has specific advantages and drawbacks that patients and physicians should understand.

Capsules and Drops

Dronabinol capsules (synthetic THC, brand name Marinol) contain a standardized dose. Effects begin after 60–90 minutes and last 4–8 hours. Oil drops (cannabis oil) are administered sublingually under the tongue — partially bypassing first-pass metabolism for slightly faster onset (30–60 minutes).

Cannabis Tea

Cannabis can be prepared as tea, but THC is lipophilic (fat-soluble) — without adding fat (butter, coconut oil), only a fraction of THC dissolves. Bioavailability is unreliable and difficult to dose.

First-Pass Metabolism: Why Less Arrives Orally

When taken orally, THC passes through the liver before reaching the bloodstream. The liver converts THC into 11-hydroxy-THC (11-OH-THC) — a metabolite that crosses the blood-brain barrier more easily and is more psychoactive than THC itself. This first-pass effect has two consequences:

Oral bioavailability is only 6–20% (compared to 30–50% with inhalation), and the effects are less predictable and highly variable between individuals.

The Overdosing Risk with Oral Intake

The delayed onset carries significant risk: the patient feels no effect after 30 minutes and takes another dose. After 60–90 minutes, both doses take effect simultaneously — an unintended overdose with intensified psychoactive side effects (anxiety, disorientation, tachycardia).

This is exactly the problem that inhalation solves: onset within 1–2 minutes enables precise titration — the patient inhales until the desired effect is reached, then stops.

Other Routes of Administration: Spray, Suppositories, Patches and Nasal Spray

Beyond inhalation and oral ingestion, several other delivery routes exist for cannabinoids. Some have reached clinical approval, while others remain experimental. The choice of route directly affects onset time, bioavailability and duration of action.

Oromucosal Administration — Sativex®

Sativex® is a cannabis extract spray applied to the oral mucosa. It contains equal parts THC and CBD and was approved in Canada in 2005 for neuropathic pain in multiple sclerosis — the first cannabis-derived pharmaceutical to achieve regulatory approval. In practice, its absorption resembles oral intake: peak plasma concentration (Tmax) occurs at roughly 100 minutes (Guy & Flint 2003). The reason is straightforward. Most of the sprayed THC gets swallowed and absorbed through the gastrointestinal tract. Only a small fraction passes directly through the mucosa into the bloodstream.

Peak plasma levels reach up to 14 ng/ml (Notcutt et al. 2001). Therapeutic effects set in after 15 to 40 minutes (Robson & Guy 2004), somewhat faster than standard oral dosing but far slower than inhalation. For context: inhalation reaches Tmax in 3 to 10 minutes, oral intake in 60 to 120 minutes, and oromucosal delivery in about 100 minutes.

Rectal Administration

For patients who can neither inhale nor swallow — due to severe nausea, vomiting or swallowing disorders — rectal administration offers a viable alternative. THC-hemisuccinate in Witepsol H15 suppositories achieved a bioavailability of roughly 13.5% in monkeys (ElSohly et al. 1991). That figure is about twice the oral bioavailability (Brenneisen et al. 1996).

Clinical studies with spinal cord injury patients showed a practical complication: higher doses were needed compared to oral administration, partly because some material was lost during application (Hagenbach et al. 2007). Rectal delivery works best as a fallback when other routes are not feasible.

Transdermal Administration (Patches)

Transdermal cannabinoid delivery remains experimental. No cannabis patch has been approved for clinical use to date. Skin permeability can be increased using water, oleic acid in propylene glycol, or ethanol at 30–33% concentration. Ethosomal carrier systems significantly improved transdermal flux in laboratory tests (Lodzki et al. 2003).

In guinea pigs, a steady-state plasma level of 4.4 ng/ml was reached within 1.4 hours and maintained for over 48 hours (Valiveti et al. 2004). In mice, steady state took about 24 hours to establish but was sustained for at least 72 hours. The key advantage: continuous, even drug delivery without the peaks and troughs of other methods. This profile could suit chronic conditions particularly well.

Intranasal Administration (Nasal Spray)

Intranasal THC delivery was first studied in rats by Valiveti et al. (2007). Peak plasma concentrations were reached after 1.5 to 1.6 hours, and the measured levels fell within the therapeutically relevant range. This route is still at an early research stage. It could eventually become an option for patients who cannot use inhalation or oral delivery.

Comparison of All Routes

Route	Tmax	Bioavailability	Duration	Application
Inhalation (Vaporizer)	3–10 min	30–40%	2–4 h	Acute symptoms, dose titration
Oral (capsules/oil)	60–120 min	6–7%	6–8 h	Long-lasting effect, nighttime pain
Oromucosal (Sativex®)	~100 min	similar to oral	4–6 h	MS spasticity, breakthrough pain
Rectal (suppositories)	variable	~13.5%	4–8 h	Nausea, swallowing disorders
Transdermal (patches)	1.4 h (steady state)	experimental	>48 h	Research stage
Intranasal (spray)	1.5–1.6 h	experimental	unknown	Research stage

For most patients, inhalation via vaporizer remains the fastest and most controllable delivery method. Oral preparations work well when long-lasting effects are needed, such as overnight pain relief. Sativex® fills a specific niche for MS patients. Rectal administration is an option when neither inhalation nor swallowing is possible. Transdermal patches and nasal sprays show early promise but need more research before they reach clinical practice.

Onset of Effect: Inhalation vs. Oral Intake

A practical advantage of vaporizing over oral consumption is speed: inhaled cannabis takes effect within 1–2 minutes and lasts 2–4 hours. When taken orally — as tea or edibles — it can take up to 90 minutes before any effect is felt.

This has direct consequences for dosing: because the effect of inhalation is felt quickly, patients can inhale gradually and stop once the desired effect is reached. With oral intake, this feedback is missing — inexperienced patients increase the dose too early because they feel nothing.

Volcano Medic 2: Balloon vs. Tube

The Volcano Medic 2 offers two inhalation methods with different efficiency. Cannabis flowers are pre-ground in the Herb Mill — increasing surface area for more even vaporization. The Filling Chamber is placed on the Hot Air Generator, preheated air flows through the material, decarboxylates the cannabinoids, and collects the aerosol in the Valve Balloon. The cooled, de-electrified balloon is fitted with a mouthpiece and can be safely used in bed or the bathtub.

With the Tube Kit, the patient inhales directly — the aerosol is not stored.

Comparison with 100 mg cannabis (19 mg THC) at 210 °C:

Method	THC in vapor	THC in blood
Valve Balloon	15 mg	10 mg
Tube Kit	15 mg	8.25 mg

Both methods produce the same amount of vapor — but the balloon delivers 21% more active compound into the blood because the patient can inhale the entire contents in a controlled manner.

Dronabinol and Cannabis Extracts

The Volcano Medic 2 can vaporize dronabinol and alcohol-based cannabis extracts in addition to flowers. A Filling Pad made of stainless steel wire mesh is placed in the Filling Chamber. The alcohol is vaporized at below 100 °C (in about 30 seconds) before the temperature is raised to 210 °C. This way, only the cannabinoids — without alcohol — reach the lungs.

Dosing Capsules

Pre-fillable Dosing Capsules are available for both devices — Volcano Medic 2 and Plus-medic/" class="vc-product-autolink">Mighty+ Medic. These can be filled in advance by care staff, family members, or the patients themselves. This simplifies adherence to prescriptions and makes daily use easier.

Pharmacodynamics: How the Body Responds to Vaporized Cannabis

Pharmacokinetics describes what the body does to the drug — absorption, distribution, metabolism. Pharmacodynamics flips the question: what does the drug do to the body? The following data from Abrams (2007) and Zuurman (2008) show how vaporized cannabis affects carbon monoxide exposure, subjective experience, and cardiovascular function — and why patients adjust their dose instinctively.

CO Exposure per Puff: Zero with Vaporization (Abrams 2007)

Abrams measured carbon monoxide exposure as AUC (area under the curve) for all 18 subjects — separately for vaporization and smoking, at each THC strength. The result was unambiguous: CO exposure during vaporization hovered near zero at every dose. During smoking, it climbed measurably with each puff.

THC Strength	CO AUC Vaporizer	CO AUC Smoked	CO per Puff (Smoked)
1.7%	−0.5	15.5	2.8
3.4%	−1.2	11.0	2.1
6.8%	−1.9	7.0	1.2

The negative values for the vaporizer mean that CO concentration in subjects’ breath actually decreased slightly during the session — no combustion gases were generated at all. The difference from smoking was highly significant statistically (p<0.001 at each THC concentration).

The right column tells its own story: CO exposure per puff from smoking dropped as THC concentration increased (2.8 at 1.7% THC down to 1.2 at 6.8% THC; p=0.003 for trend). Subjects took smaller puffs with stronger cannabis. That is real-time self-titration — the body regulating intake instinctively.

Subjective Effects and Self-Titration (Abrams 2007)

All subjects rated their subjective “high” on a visual analog scale from 0 to 100 mm. The core finding: there was no significant difference between vaporizer and smoking — at any time point or at any THC strength. Both delivery methods produced the same perceived intoxication.

The “high” increased significantly with rising THC concentration (p<0.001), regardless of method. At the same time, the number of puffs decreased at higher THC levels — but the pattern differed between methods.

THC Strength	Puffs Vaporizer	Puffs Smoked
1.7%	~10.1	~6.1
3.4%	~9.3	~6.2
6.8%	~8.6	~6.4

Subjects consistently took more puffs when vaporizing — likely because the vapor was milder than smoke. As THC concentration increased, smokers reduced their puff count more sharply than vaporizer users (p=0.029 for the interaction effect). This aligns with the CO data: smokers titrated more aggressively because airway irritation from smoke increased with larger puffs.

At study end, subjects were asked about their preference. 14 out of 18 favored the vaporizer. Only 2 chose smoking, 2 had no preference. 8 of 18 named the 3.4% THC vaporizer session as their best day — the medium dose with the lowest side-effect burden.

Zuurman Study: Precise Dose-Response Curve via Volcano (2008)

The Zuurman study at the Centre for Human Drug Research in Leiden took a different approach than Abrams. Instead of plant cannabis, they used pure dronabinol (synthetic THC) — dissolved in ethanol and pipetted onto herbal material inside the Volcano balloon. This let them control the exact milligram dose without terpenes or other cannabinoids affecting the results.

12 healthy volunteers received ascending doses of 2, 4, 6, and 8 mg THC at 90-minute intervals (cumulative dosing). The Volcano delivered remarkably consistent THC exposure: inter-individual variability in plasma levels was low — a decisive advantage over smoking, where the same quantity of cannabis produces widely different blood levels across users.

Pharmacodynamic effects were dose-dependent: heart rate, body sway, drowsiness, and subjective “high” all increased with each dose step. 5 of 12 subjects coughed during THC inhalation — but not during placebo sessions (pure ethanol on herbal material). The authors did not flag the coughing as clinically relevant.

This was the first study to deliver pure dronabinol (not plant material) to humans via a vaporizer. It proved that the Volcano works not just for cannabis flower but as a clinical drug delivery system for pure compounds — a prerequisite for pharmaceutical regulatory pathways.

The Foltin Puff Procedure: Standardized Inhalation

All clinical vaporizer studies (Abrams, Wilsey, and others) use the so-called Foltin Puff Procedure — a standardized inhalation protocol developed in the 1980s by Richard Foltin. It ensures that each subject absorbs comparable amounts of THC.

Steps per cycle:

1. Place mouthpiece and prepare (in the Wilsey variant: 30 seconds preparation time)
2. “Get ready” signal (5 seconds)
3. Inhale for 5 seconds
4. Hold breath for 10 seconds
5. Exhale
6. Wait 45 seconds
7. Repeat cycle

In the Wilsey study, subjects first took 4 puffs (at the 60-minute mark), followed by 4 to 8 flexible puffs (at 180 minutes). The flexible phase reduced the placebo effect because participants could regulate intensity themselves. In the Abrams study, subjects puffed until the vaporizer balloon was empty or they could not continue.

For patients at home, the principle simplifies to: inhale slowly and deeply, hold your breath for 5 to 10 seconds, exhale, wait about a minute, take the next puff. The pauses matter — they give THC time to cross from the alveoli into the bloodstream and prevent overly rapid dosing.

Volcano Medic 2: Complete Dosing Tables

The Volcano Medic 2 is the only desktop vaporizer with CE medical device certification (Class IIa). Storz & Bickel validated exact dosing data in clinical studies for two standardized cannabis varieties: Drug A (19% THC, high-potency dronabinol profile) and Drug B (6% THC, 7.5% CBD, balanced cannabinoid profile). All measurements were taken at 210 °C — the manufacturer-recommended standard temperature.

Drug A (19% THC) — Balloon Mode at 210 °C

Fill Amount	THC in Vapor	THC in Blood (estimated)
50 mg	7.5 mg	5.0 mg
100 mg	15.0 mg	10.0 mg
150 mg	22.5 mg	15.0 mg

Drug A (19% THC) — Tube Mode at 210 °C

Fill Amount	THC in Vapor	THC in Blood (estimated)
50 mg	7.5 mg	4.1 mg
100 mg	15.0 mg	8.25 mg
150 mg	22.5 mg	12.4 mg

Drug B (6% THC, 7.5% CBD) — Balloon Mode at 210 °C

Fill Amount	THC in Vapor	CBD in Vapor	THC in Blood	CBD in Blood
50 mg	2.4 mg	3.0 mg	1.6 mg	1.0 mg
100 mg	4.8 mg	6.0 mg	3.2 mg	2.0 mg
150 mg	7.2 mg	9.0 mg	4.8 mg	3.0 mg

Drug B (6% THC, 7.5% CBD) — Tube Mode at 210 °C

Fill Amount	THC in Vapor	CBD in Vapor	THC in Blood	CBD in Blood
50 mg	2.4 mg	3.0 mg	1.3 mg	0.55 mg
100 mg	4.8 mg	6.0 mg	2.64 mg	1.1 mg
150 mg	7.2 mg	9.0 mg	3.96 mg	1.65 mg

Tube mode delivers slightly less THC and CBD to the bloodstream than balloon mode. The reason is condensation inside the tube system. The balloon captures all vapor from a single heating cycle and delivers reproducible doses when inhaled at a steady pace. In clinical studies, balloon mode showed less variation between individual sessions.

For medical practice this means: a prescription can specify exact parameters — for example, “150 mg Drug B via balloon at 210 °C.” The patient then knows that roughly 7.2 mg THC and 9.0 mg CBD are present in the vapor, and that around 4.8 mg THC and 3.0 mg CBD reach the bloodstream. No other inhalation device on the market offers this level of dosing precision.

Dosing in Practice

The following dosing data come from clinical studies using the Mighty+ Medic at 210 °C (Vapormed brochure, based on validated studies).

Cannabis with 19% THC content:

Amount	THC in aerosol	THC in blood
50 mg	approx. 5 mg	approx. 3 mg
100 mg	approx. 9.5 mg	approx. 6 mg
150 mg	approx. 14 mg	approx. 9.5 mg

Cannabis with 6% THC and 7.5% CBD:

Amount	THC in blood	CBD in blood
50 mg	approx. 1 mg	approx. 1.1 mg
100 mg	approx. 2 mg	approx. 2.3 mg
150 mg	approx. 3 mg	approx. 3.5 mg

Small filling quantities (100 mg) at maximum temperature (210 °C) in a single session are recommended for the highest efficiency. The patient inhales until no visible aerosol is produced during exhalation.

Mighty+ Medic: Dosing with Balanced Strain (Drug B)

In addition to THC-dominant strains, balanced varieties with high CBD content are increasingly used. CBD modulates the psychoactive effects of THC — less anxiety, less euphoria, stronger anti-inflammatory component. The following table shows dosing values for a balanced strain (6% THC, 7.5% CBD) in the Mighty+ Medic at 210 °C:

Fill Amount	THC in Vapor	CBD in Vapor	THC in Blood	CBD in Blood
50 mg	1.8 mg	2.3 mg	1.0 mg	1.3 mg
100 mg	3.6 mg	4.5 mg	2.1 mg	2.6 mg
150 mg	5.4 mg	6.8 mg	3.1 mg	3.9 mg

At the same fill amount, Drug B delivers significantly less THC but substantial CBD quantities. This produces a milder psychoactive profile with stronger anti-inflammatory and anxiolytic effects — ideal for patients with spasticity, anxiety disorders, or those who tolerate THC poorly.

From Volcano Medic to Mighty+ Medic: History of Medical Vaporization

The history of medical cannabis vaporization begins in 2010, when the first Volcano Medic received TÜV certification as a Class IIa medical device — the world’s first approved inhaler for medical cannabis. It was a milestone: for the first time, physicians could prescribe an approved device for cannabis inhalation.

Volcano Medic 2 (2019)

In 2019, the Volcano Medic 2 arrived with improved technology:

The hot air generator provides digital precision temperature control (±1 °C) for reproducible results. The included Herb Mill grinds flowers to a standardized consistency, increasing the surface area by a factor of 3–4 for more even extraction. The filling chamber holds pre-ground material on the hot air generator while preheated air flows upward through the cannabis. A valve balloon and tube kit offer two inhalation methods for different patient needs.

Mighty+ Medic: Portable Medicine

The Mighty+ Medic is the portable counterpart to the stationary Volcano — also TÜV-certified as a Class IIa medical device:

The hybrid heating system combines convection (hot air) and conduction (contact heat) for maximum extraction. CoolFlow Technology cools the vapor on its way to the mouthpiece, making it gentler on the airways. The battery charges via USB-C and supports passthrough charging — use during charging is possible. For dosing, the Mighty+ Medic uses the same pre-fillable capsules as the Volcano Medic 2, which care staff can prepare in advance.

Both devices are manufactured by Storz & Bickel in Tuttlingen (Germany) and are subject to the same pharmaceutical quality standards.

Side Effects and Safety Notes

Acute side effects: The psychoactive effect of THC intensifies sensory perception and creates a sense of ease. In some cases, this can turn into dysphoria, anxiety, or panic. In patients predisposed to psychotic disorders, cannabis can trigger psychotic episodes. THC increases heart rate and can influence blood pressure — caution is advised with heart conditions. Other acute effects include fatigue, dizziness, dry mouth, and impairment of memory and time perception. Tolerance to most acute side effects develops within a few days.

Long-term risks: Cannabis can negatively affect development during puberty. Pregnant and breastfeeding women should avoid cannabis. With medical use at low doses, dependency is possible but unlikely.

Side Effects in Clinical Trials: Numbers and Comparisons

Dizziness, fatigue, dry mouth — every medication leaflet lists these. But how often do they actually occur with cannabinoids, and how do the numbers compare to placebo? The following data come from controlled clinical trials, compiled by Grotenhermen (2004).

Sativex® Approval Study: Side Effects in Detail

The Canadian approval dossier (Sativex Product Monograph, 2007) covered 166 patients on Sativex® and 162 on placebo. Reported side effect rates:

Side Effect	Sativex (n=166)	Placebo (n=162)
Dizziness	41.6%	13.0%
Fatigue	11.4%	5.6%
Nausea	10.2%	7.4%
Somnolence	8.4%	3.1%
Dry mouth	7.8%	1.9%
Feeling of intoxication	7.2%	0.6%
Disturbance in attention	6.6%	0.0%
Diarrhea	6.0%	3.1%
Euphoria	5.4%	0.6%
Disorientation	4.8%	0.0%

Dizziness topped the list by a wide margin — more than three times higher than placebo. Long-term follow-up added headache (8.7%), impaired balance (5%), depressed mood (4%), and memory impairment (3.1%). Most of these effects appeared during the first weeks and then faded.

Tolerance Development: Short-Term Versus Long-Term Data

The data from Zajicek et al. (2003/2005) are particularly telling. They followed 611 MS patients for 15 weeks and then for 52 weeks. The comparison shows how rapidly the body adapts:

Side Effect	Short-term (15 weeks)	Long-term (52 weeks)
Dizziness	50–59%	8–10%
Dry mouth	20–26%	1–2%
Gastrointestinal complaints	30–37%	9–12%
Other side effects	28–30%	7%

The numbers tell a clear story: dizziness dropped from up to 59% to below 10%, dry mouth from 26% to 1–2%. Once patients found their individually tolerable dose, side effect rates fell to levels barely distinguishable from placebo. This tolerance effect sets in within a few weeks for most acute side effects.

Dependency Rates Compared Across Substances

How does the addiction potential of cannabis stack up against other substances? Anthony et al. (1994) examined lifetime dependence prevalence in the US National Comorbidity Study among people who had used a substance at least once:

Substance	Lifetime Dependency Rate
Tobacco	32%
Opiates	23%
Alcohol	15%
Cannabis	9%

Cannabis had the lowest dependency rate among the four substances studied. In an Australian sample (Swift et al., 2001), the current dependence rate by DSM-IV criteria was 1.5%. Among heavy long-term users, however, the rate can reach up to 50%. In a medical context — lower doses, physician oversight, and a typically older patient population — the risk tends to be lower still.

Smoked Cannabis Versus Oral Intake: Different Side Effect Profiles

Not every route of administration produces the same side effects. A study from the California Compassionate Use Program in the 1970s directly compared side effects of smoked and orally consumed cannabis (Grotenhermen, Table 3):

Side Effect	Smoked (n=98)	Oral (n=257)
Dry mouth	56.5%	44.8%
Sedation	52.1%	64.0%
Dizziness	33.1%	26.8%
Ataxia (coordination impairment)	27.1%	12.8%
Elevated mood	26.6%	24.4%
Confusion	26.6%	31.6%
Anxiety	20.2%	18.8%

Oral intake caused more sedation (64% versus 52%) and confusion (32% versus 27%). The reason: when swallowed, the liver converts THC into 11-hydroxy-THC — a metabolite that is more psychoactive than THC itself. Smoked cannabis, on the other hand, led to more dry mouth and coordination problems, but allowed better dose control thanks to faster onset.

With vaporization, these profiles shift again: combustion-related respiratory effects drop out entirely, and dose titration is as precise as with smoking — without the downsides of burning plant material. Grotenhermen (2004) noted that medical users generally experience fewer side effects than recreational users. This comes down to lower doses, a higher average age, and avoiding smoking.

Contraindications and Inhalation Technique

Do not use: Patients with respiratory or lung conditions must not use the Volcano Medic 2 or Mighty+ Medic. Depending on vapor density, the aerosols can irritate the airways and lungs — even though irritation is considerably less than with smoking.

Habituation: Inexperienced users need a habituation period to find their optimal temperature. Vapor density increases with temperature — starting lower (e.g., 180 °C) can ease the transition.

Inhalation technique: The patient should inhale consciously and evenly. Laughing, yawning, and speaking during inhalation should be avoided — they interrupt airflow and can trigger coughing. Inhale until no visible aerosol is produced during exhalation.

Practical Guide for Patients

Medical cannabis vaporization follows a standardized procedure that ensures consistent dosing and optimal therapeutic effect. The following guide applies to both the Volcano Medic 2 (desktop, balloon or tube mode) and the Mighty+ Medic (portable).

Step-by-Step Procedure

1. Grind: Use the supplied Herb Mill to grind the prescribed cannabis flower to medium consistency. Avoid grinding too fine, as this increases airflow resistance.
2. Weigh: Use a precision scale to weigh the prescribed amount (typically 50–150 mg per session). Dosing Capsules hold approximately 100 mg.
3. Fill: Fill the Filling Chamber (Volcano) or Dosing Capsule (Mighty+) evenly. Do not compress the material.
4. Set temperature: Set to the prescribed temperature (usually 180–210 °C). The device indicates when the target temperature is reached.
5. Inhale: For Balloon mode — attach the balloon, fill for approximately 45 seconds, detach, inhale slowly and deeply. For Tube mode or Mighty+ — inhale slowly and steadily through the CoolFlow mouthpiece.
6. Monitor: Each balloon fill or 10–15 second inhalation delivers a defined dose. Visible aerosol indicates that active compounds remain.
7. Stop: When no more visible aerosol is produced, the fill is exhausted. Used material appears dark brown but not black (black indicates the temperature was too high).
8. Vapormed GmbH (2024). Medical Cannabis: Introduction and Administration Methods. Whitepaper. PDF Download

Temperature Recommendations by Condition

Medical Condition	Recommended Temperature	Rationale
Chronic pain	185–200 °C	Balanced THC + CBD + terpene extraction
Spasticity (multiple sclerosis)	190–210 °C	Full cannabinoid extraction including THCV
Nausea/appetite loss (chemotherapy)	180–190 °C	Lower temps prioritize THC (antiemetic)
Insomnia	200–210 °C	Higher temps extract sedative compounds (CBN, myrcene)
Anxiety/PTSD	170–185 °C	Low temps prioritize CBD and linalool, minimize THC intensity
Epilepsy	185–200 °C	Focus on CBD extraction
Neuropathic pain	190–205 °C	Full-spectrum extraction for entourage effect

Important Safety Note

Patients should always start with the lowest prescribed dose and temperature, then titrate upward based on effect and tolerability. Effects are felt within 1–2 minutes, allowing rapid dose adjustment. If dizziness or anxiety occurs, stop inhalation and wait — effects peak within 15–20 minutes and subside within 2–3 hours. Unlike oral administration, overdosing from inhalation is extremely rare due to the rapid feedback loop.

Risk Comparison at a Glance

Factor	Smoking	Vaporizing	Edibles
Lung irritation	High	Low	None
Carcinogens	Present	Minimal	None
Carbon monoxide	High	Undetectable	None
Onset time	1–3 minutes	1–3 minutes	30–90 minutes
Dose control	Difficult	Good (via temperature)	Difficult
THC metabolites in urine	High	Low	Very high

Decarboxylation and Vaporization Temperatures

In the raw cannabis plant, cannabinoids exist in their acid form — primarily THCA and CBDA. These acid forms are pharmacologically largely inactive: THCA is not psychoactive, and CBDA has minimal anti-inflammatory effect. Only through heat is the carboxyl group (-COOH) removed. This process is called decarboxylation.

THCA converts to psychoactive THC at approximately 105 °C, while CBDA converts to CBD at similar temperatures. Inhaling raw cannabis would produce virtually no therapeutic effect — the active compounds would still be trapped in their inactive precursor form. Vaporizers operate at 180–210 °C, well above the decarboxylation threshold. The conversion of THCA to THC happens completely within fractions of a second.

Which Substance Vaporizes at Which Temperature?

Cannabis contains over 100 different cannabinoids and several dozen terpenes. Each of these compounds has its own boiling point. By choosing the vaporization temperature, you can selectively control which active substances are released:

Temperature	Compound	Type	Effect / Note
~105 °C	THCA → THC	Decarboxylation	Activation of main psychoactive compound
157 °C	THC (Δ⁹-THC)	Cannabinoid	Analgesic, antiemetic, appetite stimulant
160–180 °C	CBD	Cannabinoid	Anti-inflammatory, anxiolytic, antiepileptic
166 °C	CBN	Cannabinoid	Mildly sedative, antibacterial
168 °C	Myrcene	Terpene	Sedative, muscle relaxant, synergizes with THC
176 °C	Limonene	Terpene	Mood-elevating, anti-anxiety, antibacterial
185 °C	α-Pinene	Terpene	Bronchodilator, anti-inflammatory, memory aid
198 °C	Linalool	Terpene	Anxiolytic, sedative, local anesthetic
210 °C	THCV	Cannabinoid	Appetite suppression, neuroprotective
210 °C	β-Caryophyllene	Terpene	Anti-inflammatory (CB2 agonist), gastroprotective
>220 °C	Benzene risk	Pyrolysis	Toxic byproducts begin to form
>230 °C	Increased toxin formation	Pyrolysis	Carcinogenic compounds — avoid at all costs

Temperature in Practice

Low temperatures (170–185 °C) release primarily THC and lighter terpenes — good for daytime use with clear-headed, alert effects. Medium temperatures (185–200 °C) add CBD and heavier terpenes for a more balanced, body-oriented effect. High temperatures (200–210 °C) extract the maximum amount of cannabinoids, including THCV and β-Caryophyllene. In medical vaporization, 210 °C should never be exceeded — the Volcano Medic 2 and Mighty+ Medic are factory-set to this maximum to ensure patient safety.

Some physicians recommend so-called “temperature stepping”: the session starts at 180 °C and is gradually increased to 210 °C. This way, the patient first inhales the lighter, more activating compounds, then progressively extracts the heavier, more sedating substances from the same fill. This approach uses the plant material more efficiently and gives the patient greater control over the effect profile.

Temperature and Health

Range	Health Aspect	Main Compounds
160–180 °C	Very gentle, minimal irritation	THC, CBD, Myrcene, Pinene
180–200 °C	Gentle, somewhat more vapor	THC, CBD, CBN, Linalool
200–220 °C	More vapor, mild irritation possible	CBC, THCV, higher terpenes
>230 °C	Risk of combustion — avoid	Harmful byproducts form

Practical Tips

• Start at a low temperature (170–180 °C) and increase gradually
• Take slow, steady draws rather than short, rapid puffs
• Don’t overfill the chamber — airflow ensures even heating
• Clean your device regularly to prevent residue buildup
• If you experience throat irritation: lower the temperature or try water filtration

Legal Framework in Europe

The legal status of medical cannabis varies significantly across Europe. Germany was among the first EU countries to create a comprehensive legal framework for cannabis-based medicines in 2017. Since then, other nations have followed suit — with approaches ranging from full legalization to pilot programs and regional provisions.

Germany: The Cannabis-as-Medicine Act

On March 10, 2017, the German parliament passed the “Cannabis als Medizin” law (amendment to §31 Abs. 6 SGB V). Here are the key provisions:

Physicians of any specialty can prescribe cannabis flowers, extracts, or dronabinol on a standard BtM (narcotics) prescription. Statutory health insurance covers the costs when conventional treatments have failed or cause intolerable side effects. Approval from the insurance provider is required before the first prescription (Kostenübernahmeantrag) — however, it cannot be denied for SAPV patients (specialized outpatient palliative care). Patients receive pharmaceutical-grade cannabis exclusively from pharmacies; cultivation is permitted only for the Federal Institute for Drugs and Medical Devices (BfArM), not for patients. Since April 2024 (CanG), recreational possession of up to 25 g has been legalized, while the medical prescription system remains unchanged.

European Overview

Regulations across Europe range from established programs with cost reimbursement to time-limited pilot projects. The following table shows the status in selected countries:

Country	Status	Since	Notes
Germany	Fully legal (prescription)	2017	Insurance-covered, BtM prescription
Netherlands	Fully legal (prescription)	2003	Office of Medicinal Cannabis (BMC), Bedrocan supplier
Italy	Fully legal (prescription)	2013	Military pharmaceutical facility produces cannabis
Czech Republic	Fully legal (prescription)	2013	Electronic prescription system
Poland	Fully legal (prescription)	2017	Pharmacy-dispensed, import-dependent
Denmark	Pilot program	2018	4-year trial extended, pharmacy distribution
France	Pilot program	2021	Experimentation phase, 3,000 patients
UK	Fully legal (prescription)	2018	Specialist physicians only, rarely prescribed via NHS
Spain	Regional programs	varies	Catalonia pilot (2023), no national framework
Portugal	Fully legal (prescription)	2018	Pharmacy-dispensed
Switzerland	Fully legal (prescription)	2022	No longer requires BAG special permit

The Prescription Process

In Germany, obtaining a medical cannabis prescription typically follows these steps:

1. The patient consults a physician and documents previous failed therapies
2. The physician submits a cost approval request to the health insurance provider (Kostenübernahmeantrag)
3. The insurer decides within 3–5 weeks (3 weeks standard, 5 weeks if an expert opinion is needed)
4. If approved: a BtM prescription is issued, valid for 7 days
5. The patient fills the prescription at any pharmacy
6. The physician determines: strain (e.g., Bedrocan 22% THC, Bediol 6.3% THC / 8% CBD), daily dose, and administration method — vaporizer is the recommended route
7. Follow-up: the patient reports back, dose adjustments are made as needed, and driving restrictions apply
8. Vapormed GmbH (2024). Medical Cannabis: Introduction and Administration Methods. Whitepaper. PDF Download

Medically Certified Vaporizers

Some manufacturers offer vaporizers specifically certified for medical use. These devices undergo rigorous testing and are approved as medical devices:

• Volcano Medic 2 — Desktop vaporizer by Storz & Bickel, TÜV-certified medical device
• Mighty+ Medic — Portable vaporizer by Storz & Bickel, TÜV-certified
• Graveda Medic+ — Portable medical vaporizer
• MiniVap Portable — Medically certified portable from Spain
• MiniVap Single — Compact medical variant

Device Overview: Volcano Medic 2 and Mighty+ Medic

Storz & Bickel manufactures the only two CE-certified medical vaporizers worldwide. Both devices are classified as Class IIa medical devices under the EU MDR (Medical Device Regulation). The following comparison highlights their technical specifications and intended use.

Specification	Volcano Medic 2	Mighty+ Medic
Type	Desktop	Portable
CE certification	Class IIa medical device	Class IIa medical device
Heating system	Convection (hot air)	Convection + conduction (hybrid)
Temperature range	40–230 °C (medical: 180–210 °C)	40–210 °C
Temperature precision	± 1.5 °C	± 1.5 °C
Delivery modes	Balloon (Easy Valve) + Tube	Direct inhalation (CoolFlow)
Filling chamber	100–250 mg (Filling Chamber)	~100 mg (Dosing Capsule)
Power source	AC mains (230V)	Li-ion battery (3,600 mAh)
Battery life	N/A (always plugged in)	~90 minutes / ~8 sessions
USB-C charging	N/A	Yes (passthrough charging)
Heat-up time	~40 seconds	~60 seconds
Weight	1.8 kg	135 g
Dimensions	18 × 18 × 20 cm	14 × 4.3 × 3.2 cm
Made in	Germany (Tuttlingen)	Germany (Tuttlingen)
Accessories	Herb Mill, Easy Valve Balloon, Tube, Filling Chamber, Dosing Capsules	Herb Mill, CoolFlow, Dosing Capsules, USB-C cable
Validated dosing data	Yes (Drug A + Drug B)	Yes (Drug B via Mighty+ Medic study)
Warranty	3 years	2 years
Typical use	Clinical settings, home use (stationary)	Mobile patients, on-the-go use

Quality Assurance and Storage of Medical Cannabis

Medical cannabis must meet pharmaceutical-grade standards. In the Netherlands, Bedrocan BV produces standardized cannabis under GMP (Good Manufacturing Practice) conditions — the same quality standards as conventional pharmaceuticals. Key quality requirements:

This includes standardized cannabinoid content (e.g., Bedrocan: 22% THC, <1% CBD ± 10%), gamma irradiation to eliminate microbial contamination (molds, bacteria) without degrading cannabinoids, residual solvent testing, heavy metal testing, and pesticide screening, as well as batch-to-batch consistency verified via HPLC analysis.

Storage recommendations for patients:

• Store in original pharmacy container (light-protected, airtight)
• Room temperature (15–25 °C), away from heat sources
• Avoid humidity (>65% promotes mold growth)
• Once opened: use within 4–6 weeks
• Do NOT refrigerate or freeze (moisture condensation upon warming)
• Ground cannabis loses potency faster — grind only immediately before use

Cannabis vs. Conventional Pain Therapy

Chronic pain is the most common indication for medical cannabis — 64.9% of patients receive it for this reason. But how does cannabis compare to established analgesics? The following comparison addresses the key pharmacological differences between medical cannabis, opioids, and non-steroidal anti-inflammatory drugs (NSAIDs).

Comparison of Pain Therapies

Criterion	Medical cannabis (inhaled)	Opioids (morphine, fentanyl, etc.)	NSAIDs (ibuprofen, diclofenac, etc.)
Fatal overdose risk	No known lethal dose	High — respiratory depression	Moderate — GI bleeding, renal failure
Physical dependence	Low — mild withdrawal symptoms	High — severe withdrawal syndrome	None/minimal
Addiction potential	Low to moderate (9% lifetime)	High (20–30% misuse rate)	None
Organ damage (long-term)	No known organ toxicity	Constipation, hormonal disruption, immunosuppression	Gastric ulcers, kidney damage, cardiovascular risk
Tolerance development	Moderate — dose adjustments needed	High — rapid escalation typical	Low
Drug interactions	Few — mainly CYP450 enzymes	Many — respiratory depressants, benzodiazepines	Many — anticoagulants, antihypertensives
Anti-inflammatory effect	Yes (CBD, β-caryophyllene)	No	Yes (primary mechanism)
Speed of relief (inhaled)	1–2 minutes	N/A (oral/IV)	30–60 minutes (oral)
Driving ability	Impaired for 3–4 hours	Impaired	Not typically impaired
Availability	Prescription, specialized pharmacies	Prescription (Schedule II)	Over-the-counter

Opioid-Sparing Effect

Multiple studies demonstrate that medical cannabis can reduce opioid consumption by 40–60% in chronic pain patients. A 2016 study by Bachhuber et al. found that US states with medical cannabis laws had 24.8% lower opioid overdose mortality. This opioid-sparing effect is a key argument for integrating cannabis into multimodal pain management.

Limitations of Cannabis in Pain Therapy

Cannabis is not a replacement for all conventional analgesics. For acute postoperative pain, opioids remain the standard. For inflammatory conditions like rheumatoid arthritis, NSAIDs are first-line. Cannabis is most promising as complementary therapy — reducing the required doses of conventional medications and addressing symptoms like pain, nausea, and insomnia that conventional drugs treat inadequately.

WHO Perspective

The World Health Organization’s Expert Committee on Drug Dependence concluded in 2019 that CBD has a good safety profile and is generally well tolerated. The committee recommended rescheduling cannabis-related substances under international drug control conventions, reflecting the growing evidence for therapeutic value.

Further Reading

The following publications explore specific aspects of medical cannabis therapy in greater depth:

• Russo EB. “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.” British Journal of Pharmacology. 2011;163(7):1344–1364. — Foundational work on the entourage effect between cannabinoids and terpenes.
• Whiting PF et al. “Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.” JAMA. 2015;313(24):2456–2473. — Comprehensive meta-analysis on medical cannabis for chronic pain, spasticity, and nausea.
• Grotenhermen F, Müller-Vahl K. “The therapeutic potential of cannabis and cannabinoids.” Deutsches Ärzteblatt International. 2012;109(29–30):495–501. — Overview of indications and evidence from Germany.
• National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids. Washington DC: National Academies Press; 2017. — Most comprehensive systematic assessment of cannabis health effects.
• Hazekamp A, Grotenhermen F. “Review on clinical studies with cannabis and cannabinoids 2005–2009.” Cannabinoids. 2010;5:1–21. — Review of clinical studies with focus on vaporization.

Conclusion

The body of evidence is clear: vaporizing significantly reduces exposure to harmful substances compared to smoking. Less carbon monoxide, fewer respiratory complaints, different metabolite profiles — all documented across multiple independent studies.

In medical settings, vaporizers are becoming increasingly important. Fibromyalgia patients benefit, asthma researchers recommend vaporizers as alternatives, and new animal models finally enable controlled long-term studies.

That said, vaporizing is not risk-free. Anyone with health concerns should consult a physician.

Scientific Sources

1. Abrams, D. I. et al. (2007). Vaporization as a Smokeless Cannabis Delivery System. Clinical Pharmacology & Therapeutics, 82(5), 572–578. PubMed 17429350
2. Earleywine, M. & Barnwell, S. S. (2007). Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduction Journal, 4, 11. PubMed 17437626
3. Farra, Y. M. et al. (2020). Acute neuroradiological, behavioral, and physiological effects of nose-only exposure to vaporized cannabis in C57BL/6 mice. Inhalation Toxicology, 32(5), 200–217. PubMed 32475185
4. Habib, G. & Levinger, U. (2020). Characteristics of Medical Cannabis Usage Among Patients with Fibromyalgia. Harefuah, 159(5), 343–348. PubMed 32431124
5. Huestis, M. A. et al. (2020). Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized, and Oral Cannabis Administration. Journal of Analytical Toxicology, bkaa046. PubMed 32369162
6. Jarjou’i, A. & Izbicki, G. (2020). Medical Cannabis in Asthmatic Patients. Israel Medical Association Journal, 22(4), 232–235. PubMed 32286026
7. Spindle, T. R. et al. (2022). Acute Effects of Smoked and Vaporized Cannabis. JAMA Network Open, 5(11). PMC 8975973
8. Hazekamp, A. et al. (2006). Evaluation of a vaporizing device (Volcano) for the pulmonary administration of THC. Journal of Pharmaceutical Sciences, 95(6), 1308–1317. PubMed 16552759
9. Wilsey, B. et al. (2013). Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain. The Journal of Pain, 14(2), 136–148. PubMed 23237736
10. Gieringer, D. et al. (2004). Cannabis Vaporizer Combines Efficient Delivery of THC with Effective Suppression of Pyrolytic Compounds. Journal of Cannabis Therapeutics, 4(1), 7–27. DOI
11. Hazekamp, A. (2009). The VOLCANO MEDIC cannabis Vaporizer: Effect of repeated use of a single filling. Leiden University.
12. Zuurman, L. et al. (2008). Effect of intrapulmonary THC administration in humans. Journal of Psychopharmacology, 22(7), 707–716.
13. Van der Kooy, F., Pomahacova, B. & Verpoorte, R. (2008). Vaporization as a smokeless cannabis delivery system. Leiden University.
14. Grotenhermen, F., Häußermann, K. & Milz, E. (2017). Cannabis: Verordnungshilfe für Ärzte. Stuttgart.
15. Vapormed GmbH (2024). Medical Cannabis: Introduction and Administration Methods. Whitepaper. PDF Download

Related Articles: Temperature Settings · Water Filtration

Frequently Asked Questions

Is vaporizing healthier than smoking?

Yes, studies show up to 95% fewer harmful combustion byproducts when vaporizing. No tar is produced and carbon monoxide levels are significantly lower. However, long-term studies spanning decades are still lacking.

What temperature is healthiest?

Lower temperatures (170–190 °C / 338–374 °F) produce fewer potentially harmful byproducts. Above 230 °C (446 °F), benzene and other pollutants may form. Most experts recommend 180–200 °C (356–392 °F).

Does switching from smoking to vaping improve lung health?

Several studies report improved lung function and reduced respiratory symptoms within 1–3 months of switching. Spirometry values like FEV1 show measurable improvement.

{“@context”:”https://schema.org”,”@type”:”FAQPage”,”mainEntity”:[{“@type”:”Question”,”name”:”Is vaporizing healthier than smoking?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Yes, studies show up to 95% fewer harmful combustion byproducts when vaporizing. No tar is produced and carbon monoxide levels are significantly lower. However, long-term studies spanning decades are still lacking.”}},{“@type”:”Question”,”name”:”What temperature is healthiest?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Lower temperatures (170–190 °C / 338–374 °F) produce fewer potentially harmful byproducts. Above 230 °C (446 °F), benzene and other pollutants may form. Most experts recommend 180–200 °C (356–392 °F).”}},{“@type”:”Question”,”name”:”Does switching from smoking to vaping improve lung health?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Several studies report improved lung function and reduced respiratory symptoms within 1–3 months of switching. Spirometry values like FEV1 show measurable improvement.”}}]}

Related Articles

AVB/ABV Utilization

AVB/ABV Already Vaped Bud: How to reuse your vaped herb effectively. Recipes, extraction methods, and potency tips fo…

Microdosing with Vaporizers

Microdosing with vaporizers: Scientific guide to low-dose consumption. Learn about precise temperature control, suita…

Vaporizer vs E-Cigarette: The Difference

What distinguishes a vaporizer from an e-cigarette? Function, materials, health aspects and costs compared and explai…